文献速递消化系统肿瘤

70例血清甲胎蛋白升高胃癌患者的预后与临床病理特征分析

[The prognosis and clinicopathological characteristics of 70 gastric cancer patients with elevated serum AFP].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2017-01-01

该研究回顾性纳入2006年8月至2016年5月70例血清AFP>20 ng/ml且接受至少一线治疗的晚期胃癌患者,分析其临床病理特征与预后。一线化疗后AFP下降≥50%者的疾病控制率(96.3% vs 56.7%)和总生存(17.2个月 vs 8.8个月)均优于下降<50%者;联合治疗与单纯化疗的总生存无显著差异。

要点

  • 一线化疗后AFP下降≥50%者疾病控制率96.3%,高于下降<50%者的56.7%(P=0.001)
  • AFP下降≥50%者总生存17.2个月,长于下降<50%者的8.8个月(P=0.007)
  • 联合治疗组中位总生存15.6个月,单纯化疗组11.0个月,差异无统计学意义(P=0.070)

核心结论

  • 血清AFP升高胃癌是胃癌的特殊类型,具有异质性,预后存在差异。
  • 血清AFP下降程度可能为疗效的敏感预测指标,与患者预后有关。
  • 血清AFP升高胃癌的肝转移率显著升高,联合多种治疗模式有可能改善其预后。

研究设计与样本

  • 回顾性分析2006年8月至2016年5月收治的70例晚期胃癌患者。
  • 纳入标准为病理确诊胃腺癌、治疗前血清AFP>20 ng/ml且接受至少一线治疗。
  • 收集临床病理资料与随访资料进行分析。

主要发现

  • 血清AFP≥1 000 ng/ml组肝转移率78.6%,AFP<1 000 ng/ml组57.1%,差异无统计学意义(P=0.064)。
  • 一线化疗后AFP下降≥50%组疾病控制率96.3%,高于下降<50%组的56.7%(P=0.001)。
  • AFP下降≥50%组总生存17.2个月,长于下降<50%组的8.8个月(P=0.007)。
  • 70例患者总生存0.5~50.0个月,中位总生存12.8个月。
  • 单纯化疗31例中位总生存11.0个月,联合治疗39例中位总生存15.6个月,差异无统计学意义(P=0.070)。

临床怎么用

  • 作者认为,随访中血清AFP下降程度可能作为疗效的敏感预测指标,与患者预后有关。
  • 作者认为,联合多种治疗模式有可能改善血清AFP升高胃癌患者的预后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study aimed to review the clinicopathological characteristics and prognosis of advanced gastric cancer patients with elevated serum Alpha-fetoprotein (AFP). Methods: From August 2006 to May 2016, 70patients with advanced gastric cancer were enrolled retrospectively. All these patients had pathologically confirmed gastric adenocarcinoma, had a serum AFP level of more than 20 ng/ml, and received at least first-line treatment. The clinicopathological data and follow-up data were collected for analysis. Results: Liver metastasis was more common in patients with AFP≥1 000 ng/ml, compared with AFP<1 000 ng/ml patients (78.6% vs 57.1%, P=0.064). In patients whose AFP level decreased ≥50% after first-line chemotherapy, the disease control rate and overall survival were both better than those in patients with AFP decreased <50%(96.3% vs 56.7%, P=0.001; 17.2 m vs 8.8 m P=0.007). The overall survival of all these 70 patients ranged from 0.5-50.0 months. 31 patients received chemotherapy only, and 39 patients received combined therapy modality. The overall survival of these two groups were similar(11.0 m and 15.6 m, respectively, P=0.070). Conclusions: Serum AFP-elevated gastric cancer is a special subtype of gastric cancer. It's a heterogeneous cancer with different clinical outcomes. The extent of decrease of serum AFP level during follow-up may be a sensitive prognostic and predictive biomarker. Liver metastasis were more common in these patients, and combined treatment may improve survival. 目的: 探讨血清甲胎蛋白(AFP)升高的晚期胃癌患者的临床病理特征和预后。 方法: 回顾性分析2006年8月至2016年5月经病理确诊的治疗前血清AFP>20 ng/ml,且接受了至少一线治疗70例晚期胃癌患者的临床病理资料,分析影响AFP升高晚期胃癌患者的预后因素。 结果: 血清AFP≥1 000 ng/ml和血清AFP<1 000 ng/ml患者的肝转移率分别为78.6%和57.1%,差异无统计学意义(P=0.064)。一线化疗后AFP下降≥50%和AFP下降<50%患者的疾病控制率分别为96.3%和56.7%(P=0.001);血清AFP下降≥50%患者的总生存时间(OS)为17.2个月,长于化疗后血清AFP下降<50%的患者(8.8个月),差异有统计学意义(P=0.007)。70例血清AFP升高胃癌患者的OS为0.5~50.0个月,中位OS为12.8个月。70例患者中,接受单纯化疗31例,接受联合治疗(包括联合靶向治疗、肝介入、放疗和手术等治疗手段)39例。单纯化疗患者的中位OS为11.0个月,联合治疗模式患者的中位OS为15.6个月,差异无统计学意义(P=0.070)。 结论: 血清AFP升高胃癌是胃癌的一个特殊类型,具有异质性,预后存在差异。血清AFP的下降程度可能为疗效的敏感预测指标,与患者的预后有关。血清AFP升高胃癌的肝转移率显著升高,联合多种治疗模式有可能改善血清AFP升高胃癌患者的预后。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang YK, Shen L, Zhang XT, et al. [The prognosis and clinicopathological characteristics of 70 gastric cancer patients with elevated serum AFP]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28728297. doi:10.3760/cma.j.issn.0253-3766.2017.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。